Form 4 for COCP Cocrystal Pharma, Inc.

Accepted 2025-10-30 00:00:00 ET · period of report 2025-10-28 · accession 0001493152-25-020219 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-10-30	2025-10-28	COCP	PFENNIGER RICHARD C JR	Dir	A - Grant	—	+20.0K	31.4K	+175%	—
D	2025-10-30	2025-10-28	COCP	PFENNIGER RICHARD C JR	Dir	A - Grant	$1.39	+40.0K	40.0K	New	+$55.6K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-10-28	A	A	20,000	—	31,400	D	—	—	(F1) The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock.The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance. (F2) Includes shares of common stock issuable upon vesting of restricted stock units.
2	Derivative	Warrants	2025-10-28	A	A	40,000	$1.39	40,000	D	$1.24 · — to 2028-01-28	40,000 Common Stock	(F1) The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock.The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance.